New developments in migrane prophylaxis

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 4, 2003, Pages 433-443

  Bigal, Marcelo E ^a,b   Krymchantowski, Abouch V ^c,d   Rapoport, Alan M ^b,e  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NEW ENGLAND CENTER FOR HEADACHE   (United States)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^d Instituto de Neurologia Deolindo Couto   (Brazil)

^e Columbia Univ Coll Physician/Surg ^*  (United States)

Author keywords

Migrane; Preventive treatment; Prophylactic treatment

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETIRACETAM; GABAPENTIN; LISINOPRIL; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; MONTELUKAST; NADOLOL; NORTRIPTYLINE; PHENELZINE; PROPRANOLOL; QUETIAPINE; TIAGABINE; TIMOLOL; TIZANIDINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROEX; VALPROIC ACID; ZONISAMIDE;

ACUPUNCTURE; ALOPECIA; ASTHENIA; ATAXIA; BRAIN FUNCTION; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; GASTROINTESTINAL SYMPTOM; HEPATITIS; HUMAN; HYPERANDROGENISM; INFECTION; LANGUAGE DISABILITY; LEUKOPENIA; LIVER FAILURE; LIVER TOXICITY; MEDICAL DECISION MAKING; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; MIGRAINE; MYOPIA; NAUSEA; NEPHROLITHIASIS; NEUROLOGIC DISEASE; PANCREATITIS; PARESTHESIA; POPULATION RESEARCH; PROPHYLAXIS; PSYCHOMOTOR DISORDER; REVIEW; SOMNOLENCE; SPEECH DISORDER; TASTE DISORDER; TREATMENT FAILURE; TREMOR; UNITED STATES; VERTIGO; VOMITING; ADULT; CONTROLLED CLINICAL TRIAL; EXPERT WITNESS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUPUNCTURE; ADULT; ANTICONVULSANTS; EXPERT TESTIMONY; HUMANS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; UNITED STATES;

EID: 0037399132     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.4.433     Document Type: Review

References (70)

1. SCHER AI, STEWART WF, LIPTON RB: Migraine and headache: a meta-analytic approach. In: Epidemiology of pain. Crombie IK (Ed.), IASP press, Seattle, USA (1999):159-170.
2. STEWART WE SHECHTER A, LIPTON RB: Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology (1994) 44(Suppl. 4):S24-S39.
3. LIPTON RB, STEWART WF: Prevalence and impact of migraine. Neurol. Clin. (1997) 15:1-13.
4. BLUMENTHAL HJ, RAPOPORT AM: The clinical spectrum of migraine. In: The Medical Clinics of North America vol 85. Mathew NT (Ed.), WB Saunders, Philadelphia, USA (2001):897-909.
5. WELCH KM, D'ANDREA G, TEPLEY N et al: The concept of migraine as a state of central neuronal hyperexcitability. Neurol. Clin. (1990) 8:817-828.
6. WELCH KM, BARKLEY GL, TEPLEY N et al.: Central neurogenic mechanisms of migraine. Neurology (1993) 43:S21-S25.
7. LAURITZEN M: Pathophysiology of the migraine aura. The spreading depression theory. Brain (1994) 117:199-210.
8. LANCE JW LAMBERT GA, GOADSBY PJ, DUCKWORTH JW. Brainstern influences on the cephalic circulation: experimental data from cat and monkey of relevance to the mechanism of migraine. Headache (1983) 23:258-265.
9. WELCH KM, NAGESH V, AURORA SK, GELMAN N: Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache (2001) 41:629-637.
10. 2+ channel gene CACNLA4. Cell (1996) 87:543-552.
11. WELCH KM, RAMADAN NM: Mitochondria, magnesium and migraine. J. Neurol. Sci. (1995) 134:9-14.
12. MATHEW NT, SILBERSTEIN SD: Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Monagr. Clin. Neurosci. Diener C (Ed.), S Karger AG, Basel, Switzerland (2000):288-298.
13. MATHEW NT, SAPER JR, SILBERSTEIN SD et al: Migraine prophylaxis with divalproex. Arch. Neurol. (1995) 52:281-286.
14. SILBERSTEIN SD, COLLINS SD: Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term safety of depakote in headache prophylaxis study group. Headache (1999) 39:633-643.
15. CUTRER FM, LIMMROTH V, AYATA G, MOSKOWITZ MA: Valproate reduces C-Fos expression in trigeminal nucleus caudalis (TNC) after noxious meningeal stimulation Cephalgia (1995) 15(Suppl. 14):S96 (Abstract).
16. CUTRER FM, MOSKOWITZ M: Actions of valproate and neurosteroids in a model of trigeminal pain. Headache (1996) 36:579-585.
17. SILBERSTEIN SD, GOADSBY PJ: Migraine: preventive treatment. Cephalaigia (2002) 22:491-512.
18. HERING R, KURITZKY A: Sodium valproate in the prophylactic treatment of migraine: a double-blind study versus placebo. Cephalalgia (1992) 12:81-84.
19. JENSEN R, BRINK T, OLESEN J: Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled crossover study. Neurology (1994) 44:647-651.
20. KLAPPER J: Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia (1997) 17:103-108.
21. KANIECKI RG: A comparative study of propranolol and divalproex sodium in the prophylaxis of migraine. Arch. Neurol (1997) 54:1141-1144.
22. FREITAG FG, COLLINS SD, CARLSON HA et al: A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology (2002) 58:1652-1669.
23. PELLOCH JM, WILLMORE LJ: Rational guide to routine blood monitoring in patients receiving anti-epileptic drugs. Neurology (991) 41:961-964.
24. DRIEFUSS FE, SANTILLI N, LANGER DH, SWEENEY KR MOLINE KA, MENANDER KB: Valproic acid hepatic fatalities: a retrospective review. Neurology (1987) 37:379-385.
25. VAINIONPAA LK, RATTYA J, KNIP M et al: Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann. Neurol (1999) 45:444-450.
26. SILBERSTEIN SD: Divalproex sodium in headache - literature review and clinical guidelines. Headache (1996) 36:547-555.
27. MATHEW NT, SILBERSTEIN SD: Anticonvulsants in migraine prophylaxis. In: Drug Treatment of Migraine and Other Headaches. Diener HC (Ed.), S Karger AG, Basel, Switzerland (2000) 17:295.
28. SHACHTER SC: Epilepsy. Neurol. Clin. (2001) 19:57-78.
29. GRAM L: Pharmacokinetics of new antiepileptic drugs. Epilepsia (1996) 37(Suppl. 6):S12-S16.
30. TAYLOR CP, GEE NS, SU TZ, et al: A summary of mechanistic pharmacology of gabapentin. Epilepsy Res. (1998) 29:233-249.
31. MATHEW NT: Gabapentin in migraine prophylaxis. Cephalalgia (1996) 16:367 (Abstract).
32. MATHEW NT, RAPOPORT A, SAPER J, et al.: Efficacy of gabapentin in migraine prophylaxis. Headache (2001) 41:119-128.
33. DODGSON SJ, SHANK RP, MARYANOFF BE: Topiramate as an inhibitor of carbonic anhydrase isoenzymes Epilepsia (2000) 41:35-39.
34. A and NMDA receptor channels by phosphorilation. J. Receptor Signal Transduct. Res. (1995) 15:325-332.
35. GIBBS JW, SOMBATI S, DELORENZO RJ, COULTER DA. Cellular actions of topiramate: blockade of kainite-evoked inward currents in cultured hippocampal neurons. Epilepsia (2000) 41:S1O-S16.
36. SHUAIB A, AHMED F, MURATOGLU M, KOCHANSKI P: Topiramate in migraine prophylaxis: a pilot study. Cephalalgia (1999) 19:379-380 (Abstract).
37. KRUSZ JC, SCOTT V: Topiramate in the treatment of chronic migraine and other headaches. Headache (1999) 39:363 (Abstract).
38. EDWARDS KR, GLANTZ MJ, SHEA P, NORTON JA, CROSS N: Topiramate for migraine prophylaxis: a double-blind randomized, placebo-controlled study. Headache (2000) 40:407 (Abstract).
39. POTTER DL, HART DE, CALDER CS, STOREY JR. A double-blind, randomized, placebo-controlled, parallel study to determine the efficacy of topiramate in the prophylactic treatment of migraine. Neurology (2000) 54(Suppl. 3):A15 (Abstract).
40. SILBERSTEIN S, KARIN R, JORDAN D, HULIHAN J: Treatment effect for topiramate in migraine prophylaxis: utility of repeated measures and weighted regression analyses. Cephalalgia (2002) 22:610 (Abstract).
41. EDWARDS KR, KAMIN M: The beneficial effect of slowing the initial titration rate of topiramate. Neurology (1997) 48:A39 (Abstract).
42. DRAKE JR ME, KAY AM, KNAPP MS, GREATHOUSE NI: An open-label trial of tiagabine for migraine prophylaxis. Headache (1999) 39:352 (Abstract).
43. FREITAG FG, DIAMOND S, DIAMOND ML, URBAN GJ, PEPPER B, MOORE K: The prophylaxis of migraine with the GABA-agonist, tiagabine: a clinical report. Headache (1999) 39:354 (Abstract).
44. KRUSZ JC: Levetiracetam as prophylaxis for resistant headaches. Cephalalgia (2001) 21:373 (Abstract).
45. DRAKE ME, GREATHOUSE NI, ARMENTBRIGHT AD, RENNER JB: Levetiracetam for preventive treatment of migraine. Cephalalgia (2001) 21:373 (Abstract).
46. PRICE MJ: Levetiracetam: preventive therapy in migraine. Headache (2002) 42:455-456 (Abstract).
47. DRAKE ME, GREATHOUSE NI, ARMENTBRIGHT AD, RENNER JB: Preventive treatment of migraine with zonisamide. Cephalalgia (2001) 21:374 (Abstract).
48. KRUSZ J C: Zonisamide in the treatment of headache disorders. Cephalalgia (2001) 21:374-375 (Abstract).
49. SCHRADER H, STOVNER LJ, HELDE G, SAND T, BOVIM G: Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomized, placebo-controlled, crossover study. Br. Med. J. (2001) 322:19-22.
50. SKIDGEL RA, ERDOS EG: The broad substrate specificity of human angiotensin converting enzyme. Clin. Exp. Hypertens. (1987) 9:243-259.
51. PARANTAINEN J, VAPAATALO H, HOKKANEN E: Clinical aspects of Prostaglandins and leukotrienes (LT) in migraine. Cephalalgia (1986) 6(Suppl. 4):S95-S101.
52. SHEFTELL F, RAPOPORT A, WEEKS R, WALKER PA, GAMMERMAN I, BASKIN S: Montelukast in the prophylaxis of migraine: a potential for leukotriene modifiers. Headache (2000) 40:158-163.
53. BRANDES JL, SCHUHL AL, FARMER MV, MALBEQW, VISSER W: Preventive treatment of migraine headache with montelukast. Headache (2002) 42:451 (Abstract).
54. SMALL JG, HIRSCH SR, ARVANITIS LA, MILLER BG, LINK CG Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatry. (1997) 54:549-557.
55. BRANDES JL, ROBERSON SC, PEARLMAN SH, ABU-SHAKRA S: Quetiapine for migraine prophylaxis. Headache (2002) 42:450-451.
56. SAPER JR, LAKE AE, CANTRELL DT WINNER PK, WHITE JR: Chronic daily headache prophylaxis with tizanidine: a double blind, placebo controlled, multicenter outcome study. Headache (2002) 42:470-482.
57. ZAIMIS E, HANINGTON E: A possible pharmacological approach to migraine. Lancet (1969) 2:298-300.
58. KRUSZ JC, BELANGER J, MILLS C: Tizanidine: a novel effective agent for the treatment of chronic headaches. Headache (2000) 11:41-45.
59. SIMPSOM LL: The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. (1981) 33:155-188.
60. VOLKNANDT W: Commentary: the synaptic vesicle and its targets. Neuroscience (1995) 64:277-300.
61. BINDER W. BRIN MF, BLITZER A, SCHOENROTCK L, DIAMOND B: Botulinum toxin type A (BTX-A) for migraine: an open label assessment. Mov. Disord. (1998) 13(Suppl. 2):S241 (Abstract).
62. SILBERSTEIN SD, MATHEW NT, SAPER J, JENKINS S: Botulinum toxin type A as a migraine preventive treatment. Headache (2000) 40:445-450.
63. MATHEW NT, KAILASAN J, MEADORS L:'Disease modification' in chronic migraine with botulinum toxin type A: a long term experience. Headache (2002) 42:254.
64. EATON J: Butterbur, herbal help for migraine. Nat. Pharm. (1998) 2:23-24.
65. LIPTON RB, GOBEL H, WILKS K, MAUSKOP A: Efficacy of petasites (an extract from Petasites rhizome) 50 and 75 mg for prophylaxis of migraine: results of a randomized, double-blind, placebo controlled study. Neurology (2002) 58:A472.
66. LIN H, CHIEN CH, LIN YL et al: Inhibition of testosterone secretion by S-petasin in rat testicular interstitial cells. Chin. J. Physiol. (2000) 43:99-103.
67. STEGELMEIER BL, EDGAR JA, COLEGATE SM et al.: Pyrrolizidine alkaloid plants, metabolism and toxicity. J. Nat. Toxins (1999) 8:95-116.
68. DOWSON DI, LEWITH GT, MACHIN D; The effects of acupuncture versus placebo on the treatment of headache. Pain (1985) 21:35-42.
69. ALLAIS G, DE LORENZO C, QUIRICO P et al: Acupuncture in the prophylactic treatment of migraine without aura: a comparison with flunarizine. Headache (2002) 42:855-861.
70. KRYMCHANTOWSKI AV, BIGAL ME, MOREIRA PF: New and emerging prophylactic agents for migraine. CNS Drugs (2002) 16:611-634.